Company Overview - Molecular Partners is a clinical-stage biotech company founded in 2004, with operations and listings in Switzerland (SIX, 2014) and the US (Nasdaq, 2021)[12] - The company is financed with approximately USD 116 million / CHF 93 million to reach upcoming value inflection points[12] - Molecular Partners focuses on oncology with differentiated assets like MP0712 (targeted radiotherapy) and MP0533 (next-gen immune cell engagers)[12] Radio-DARPin Therapeutics (RDT) - The company is developing Radio-DARPin therapeutics, which are designed for precise delivery of potent radio-isotopes to tumors[26, 27] - Molecular Partners has a global partnership with Orano Med to develop 212Pb Radio-DARPin therapeutics, with a 50:50 cost and share split for 4 programs[33, 36] - MP0712, a 212Pb x DLL3 Radio-DARPin, is in Phase 1/2a clinical trials in the US for small cell lung cancer (SCLC) and other neuroendocrine cancers (NECs), with early data expected in 2026[43, 77] - Preclinical data for MP0712 shows high tumor accumulation (Tumor > Kidney) and reduction of established tumors in mice[51] - MP0726, a 212Pb x MSLN Radio-DARPin, is being developed for ovarian cancer and is progressing towards first-in-human (FIH) imaging[86, 94] Other Pipeline Programs - MP0317, a FAP-localized CD40 agonist, is in a Phase 2 combo study in advanced biliary tract cancer, with interim analysis expected by YE 2027[104, 117, 123] - MP0533, a tetra-specific T-cell engager for AML, is in Phase 1/2a, with decisional data expected in H1 2026[124] - The company is developing Switch-DARPin platform for next-generation T cell engagers, with a lead candidate selection expected in H1 2026 and an update at AACR 2026[99, 140] Financial Outlook - The company's cash of approximately USD 116 million (CHF 93 million) ensures funding until 2028[99]

Financial Performance & Cash Position - Zevra exited Q3 2025 with a strong cash position of $230.4 million[8], and total debt of $61.3 million[44] - The company generated net revenue of $72.3 million in the 9-month period[8], and $26.1 million for Q3 2025[43] - Q3 2025 net loss was $(0.5) million, or $(0.01) per basic and diluted share[43] Product Portfolio & Pipeline - MIPLYFFA adoption achieved in approximately 40% of diagnosed Niemann-Pick Disease Type C (NPC) patients within the first year of launch[13] - Payor coverage for MIPLYFFA reached 66% of covered lives as of Q3 2025[24] - Approximately 80% of patients who participated in the Phase 2/3 clinical trial for MIPLYFFA took miglustat[20] - Celiprolol Phase 3 DiSCOVER trial is ongoing for Vascular Ehlers-Danlos Syndrome (VEDS), with 44 of 150 patients enrolled as of Q3 2025[40] - For VEDS patients on celiprolol, the annual major vascular event rate is approximately 5% compared to approximately 12% in untreated patients[40] Market & Regulatory - Approximately 900 individuals in the U S live with NPC, of which 300-350 are diagnosed or treated[27] - Approximately 1,100 individuals are living with NPC in Europe[27] - MAA for Arimoclomol is under review by the EMA[8, 13]

CG Oncology (NasdaqGS:CGON) FY Conference January 15, 2026 11:15 AM ET Speaker3Good morning, everyone. Thanks for joining us for another session at the 44th J.P. Morgan Healthcare Conference. I'm Brian Cheng. I'm one of the senior biotech analysts here at the firm. On stage, we have CG Oncology. I'll now pass the mic to their CEO, Arthur Kuan, for a short presentation followed by a live audience Q&A. Arthur, welcome. The stage is yours.Speaker2Thank you, Brian. Good morning, everyone. So at CG Oncology, we' ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Skye To Contact Him Directly To Discuss Their Options If you purchased or acquired Skye securities between November 4, 2024 and October 3, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & ...

Key Takeaways HiFi sequencing is adopted as a first-line approach in a major SUDC study sequencing 200 family trios.PACB shares rose 10.8% after reporting preliminary 2025 revenue of $160M, with Q4 revenue of $44.6M.PACB's Revio with SPRQ-Nx aims to boost throughput, data quality and lower costs for complex genetic cases.Pacific Biosciences of California, Inc. (PACB) , popularly known as PacBio, recently announced that its HiFi whole-genome sequencing technology has been adopted as a first-line approach in ...

Structure Therapeutics Inc. (NASDAQ:GPCR) is among the 14 best booming stocks to buy right now. The company’s shares have gained over 130% in the past three months, with a major surge since early December after reporting positive data related to its oral obesity pill. Structure Therapeutics Inc. (GPCR) Has Gained Over 130% in 3 Months. Here is Why Stock market data showing an upward trajectory. Photo by Burak The Weekender on Pexels A study testing aleniglipron on obese or overweight patients, with one ...

Vera Therapeutics, Inc. (NASDAQ:VERA) is among the 14 best booming stocks to buy right now. On January 7, the company announced that the U.S. Food and Drug Administration (FDA) had accepted Atacicept’s Biologics License Application (BLA) for priority review to treat adult patients of immunoglobulin A nephropathy (IgAN). Vera Therapeutics, Inc. (VERA) Granted FDA Priority Review For Atacicept The application was submitted under the Accelerated Approval Program and has been granted a target action date of ...

Dyne Therapeutics, Inc. (NASDAQ:DYN) is among the 14 best booming stocks to buy right now, with returns of over 23% in the last three months. Wall Street analysts have a consensus Strong Buy rating on the stock and project a further 120% upside as of the close on January 12. Analysts Project 120% Upside To Dyne Therapeutics, Inc. (DYN) Recent analyst updates include Evercore ISI’s Gavin Clark-Gartner on December 17, trimming the firm’s price target on the stock to $36 from $38, while maintaining an earli ...

Key Takeaways Eli Lilly's Mounjaro and Zepbound generated $24.8 billion in nine months, making up 54% of total revenues.Improved supply and new international launches are fueling strong sales momentum for both drugs.Lilly's oncology, immunology and neuroscience drugs also continue to support top-line expansion.Eli Lilly (LLY) has emerged as a dominant force in the cardiometabolic market, driven by strong demand for its blockbuster GLP-1 therapies, Mounjaro for type II diabetes (T2D) and Zepbound for obesity ...

Financial Data and Key Metrics Changes - The meeting discussed the approval of the Continuance Resolution and Domestication Resolution, which were passed by a majority of not less than two-thirds of the votes cast [19] - The 2026 Incentive Award Plan was also approved by a majority of the votes cast [19] Business Lines Data and Key Metrics Changes - No specific data or metrics related to individual business lines were provided during the meeting Market Data and Key Metrics Changes - No specific market data or metrics were discussed during the meeting Company Strategy and Development Direction - The company is transitioning from Alberta to British Columbia and then domesticate to Nevada, indicating a strategic shift in its operational base [9][12] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during this meeting Other Important Information - The meeting was conducted virtually, ensuring shareholder rights were protected and allowing participation similar to in-person meetings [3][4] - The voting results will be filed on SEDAR and made available on the company's website [20] Q&A Session Summary - No specific questions were raised during the meeting regarding the motions presented [12][15][18][22]